Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe nonproliferative diabetic retinopathy (NPDR) \[(diabetic retinopathy severity scale (DRSS) levels 47 or 53)\], confirmed by the central reading center, in whom panretinal photocoagulation (PRP) can be safely deferred for at least 6 months per the investigator~2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)~Key Exclusion Criteria:~1. Presence of diabetic macular edema (DME) threatening the center of the macula in the study eye~2. Evidence of retinal neovascularization on clinical examination or Fluorescein Angiography (FA)~3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye~4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or intravitreal (IVT) anti-VEGF treatment in the study eye~5. Any prior intraocular steroid injection in the study eye~6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye~Note: Other inclusion/ exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing regimen 1 (Type: EXPERIMENTAL): Participants will receive IVT aflibercept dosing regimen 1
- Dosing regimen 2 (Type: EXPERIMENTAL): Participants will receive IVT aflibercept dosing regimen 2
- Dosing regimen 3 (Type: SHAM_COMPARATOR): Participants will receive matching sham injections

Based on this trial design, predict the completion outcome and termination type (if applicable).